GD
BMRN icon

Grandfield & Dodd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Grandfield & Dodd’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Sell
17,861
-290
-2% -$16.9K 0.06% 110
2025
Q4 		$1.08M Sell
18,151
-816
-4% -$44.4K 0.06% 112
2025
Q3 		$1.03M Buy
18,967
+217
+1% +$12.4K 0.06% 111
2025
Q2 		$1.03M Buy
18,750
+38
+0.2% +$2.24K 0.06% 106
2025
Q1 		$1.32M Buy
18,712
+1,320
+8% +$88.8K 0.08% 98
2024
Q4 		$1.14M Buy
17,392
+731
+4% +$49K 0.07% 104
2024
Q3 		$1.17M Buy
16,661
+425
+3% +$35.5K 0.07% 102
2024
Q2 		$1.34M Buy
16,236
+109
+0.7% +$9.07K 0.08% 98
2024
Q1 		$1.41M Buy
16,127
+255
+2% +$22.8K 0.09% 97
2023
Q4 		$1.53M Buy
15,872
+219
+1% +$19.4K 0.11% 91
2023
Q3 		$1.38M Sell
15,653
-125
-0.8% -$11.1K 0.1% 91
2023
Q2 		$1.37M Buy
15,778
+137
+0.9% +$12.9K 0.1% 91
2023
Q1 		$1.52M Buy
15,641
+231
+1% +$23.9K 0.11% 87
2022
Q4 		$1.59M Buy
15,410
+1,037
+7% +$97.4K 0.12% 85
2022
Q3 		$1.22M Buy
14,373
+372
+3% +$33.1K 0.1% 91
2022
Q2 		$1.16M Buy
14,001
+75
+0.5% +$5.97K 0.09% 91
2022
Q1 		$1.07M Buy
13,926
+456
+3% +$38.2K 0.07% 99
2021
Q4 		$1.19M Buy
13,470
+1,337
+11% +$110K 0.08% 93
2021
Q3 		$940K Buy
12,133
+399
+3% +$31.5K 0.07% 104
2021
Q2 		$980K Buy
11,734
+215
+2% +$17K 0.07% 100
2021
Q1 		$870K Buy
11,519
+280
+2% +$22.9K 0.07% 104
2020
Q4 		$990K Buy
11,239
+439
+4% +$34.8K 0.08% 100
2020
Q3 		$820K Buy
10,800
+167
+2% +$16.9K 0.07% 100
2020
Q2 		$1.31M Buy
10,633
+695
+7% +$69.1K 0.13% 81
2020
Q1 		$840K Buy
9,938
+525
+6% +$45.2K 0.1% 92
2019
Q4 		$796K Buy
9,413
+950
+11% +$71.8K 0.07% 107
2019
Q3 		$570K Buy
8,463
+930
+12% +$71.6K 0.06% 121
2019
Q2 		$645K Buy
7,533
+665
+10% +$56.9K 0.06% 116
2019
Q1 		$610K Buy
6,868
+112
+2% +$10.4K 0.06% 116
2018
Q4 		$575K Buy
6,756
+94
+1% +$8.94K 0.07% 112
2018
Q3 		$646K Buy
6,662
+70
+1% +$6.99K 0.07% 117
2018
Q2 		$621K Buy
6,592
+45
+0.7% +$3.94K 0.07% 117
2018
Q1 		$531K Sell
6,547
-240
-4% -$20.6K 0.06% 118
2017
Q4 		$605K Buy
6,787
+290
+4% +$25.2K 0.06% 121
2017
Q3 		$605K Buy
6,497
+650
+11% +$57.4K 0.07% 117
2017
Q2 		$531K Buy
5,847
+120
+2% +$10.9K 0.06% 125
2017
Q1 		$503K Buy
5,727
+65
+1% +$5.78K 0.06% 126
2016
Q4 		$469K Buy
5,662
+535
+10% +$46K 0.06% 126
2016
Q3 		$474K Buy
5,127
+280
+6% +$26.4K 0.06% 123
2016
Q2 		$377K Buy
4,847
+188
+4% +$16K 0.05% 132
2016
Q1 		$384K Buy
4,659
+1,785
+62% +$145K 0.06% 125
2015
Q4 		$301K Buy
2,874
+545
+23% +$56.9K 0.05% 144
2015
Q3 		$245K Sell
2,329
-183
-7% -$24.4K 0.04% 152
2015
Q2 		$344K Sell
2,512
-196
-7% -$24.3K 0.05% 134
2015
Q1 		$337K Hold
2,708
– – 0.05% 129
2014
Q4 		$245K Buy
+2,708
New +$225K 0.04% 150

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grandfield & Dodd's BMRN Position: Q1 2026 in Review

Grandfield & Dodd reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.6% in Q1 2026, selling an estimated $16.9K and leaving 17,861 shares worth $1.01M. The position accounts for 0.06% of the portfolio, ranked #110.

Grandfield & Dodd first reported a position in BMRN in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.59M in Q4 2022. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Grandfield & Dodd held 17,861 shares of BioMarin Pharmaceuticals worth $1.01M as of Q1 2026.
  • Grandfield & Dodd sold 290 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $16.9K.
  • BioMarin Pharmaceuticals made up 0.06% of Grandfield & Dodd's portfolio in Q1 2026, its #110 holding.
  • Grandfield & Dodd first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • Grandfield & Dodd's BioMarin Pharmaceuticals position peaked at $1.59M in Q4 2022.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.